KLSC aims to be the Middle East’s premiere Life Sciences Company achieving superior returns from innovative regional operations and global investments.
Invest in Best-in-Class and proven life sciences and healthcare companies and transfer their technology into the Middle East via KLSC’s existing strategic platforms
Support innovative regional investments and business models by leveraging our international presence and network
Champion a Foundational Gateway for innovative global investment opportunities into the Middle East through our Regional Value Added Operations
Expand our integrated Life Sciences Platform to provide unique and inventive products and services to the Middle East
Embrace entrepreneurship as an essential component for growing the nascent Middle East Life Sciences and Healthcare industry and as an important pillar of a Knowledge Economy
eCore is involved in:
Providing industrials and specialty chemical solutions for: (our sectors are Food industry/ Pharmaceutical Industry/ Home and Personal Care Industries/ Animal Feed industry/
Innomedics aims to improve the efficiency of the healthcare services and encourage value based medicine by providing the most efficient and best value medical equipment and consumables
Innomedics delivers innovative technologies in health care sector through medical professionals, institutions and directly to the consumers via partnerships with local pharmacy and retail distributors
Innomedics is a regional distributor of medical technology in the GCC region that provides innovative medical solutions to healthcare service providers
Innomedics Business Units
Providing world class medical devices and consumables in the follow subsectors:
Clinart contributes to improve the ability for pharma, biotech and medical devices companies, academia and governments to host world-class clinical trials in the MENA region
Clinart provides quality services with a proven track record of successful trials in the MENA region (phase II-IV) since 2001
Clinart MENA is a Contract Research Organization (CRO) headquartered in Dubai, Healthcare City offering a Full Service End-to-End solution that brings Clinical Research expertise to the Middle East region in line with local cultures and customs
Developing, Planning, Conducting and Managing clinical trials for:
NewBridge aims to improve the access for ‘big pharma’ companies, genomics and biologics manufacturers to the MENA region
NewBridge pharmaceuticals is a regional specialty company providing one-stop-solution to pharmaceuticals, biological, genomics and other innovative healthcare companies
NewBridge is the exclusive licensor of pharmaceutical products in:
Oncology (Astral®, Aware®, Clasteon™, Halaven, M2PK®, Oncotype Dx®, Sancuso), Immunology (Cimzia®) , Nutrition(Celia®, Delicel®, RealDiet™, Taranis®), CNS Care (Ebenet® Diabase), Dermatology, (Glinconorm®, Pylera®), Metabolic Care (Neupro®, Vimpat®), Woman’s Health (Femmed®)
New Bridge Subsectors
Providing pharmaceutical commercialization of drugs in the following subsectors:
KLSC follows a similar investment strategy according to its parent company, NTEC, focusing on the following three pillars
KLSC invests in the project’s equity in partnership with the private sector entrepreneur or company and accommodates KLSC’s main strategic goal of technology transfer into Kuwait and the MENA region.These projects are internally developed by KLSC and externally developed by the private sector. In both cases, KLSC usually favors the formation of a Joint Venture, partnering with technology providers, supporting projects that add value, meet a local or regional demand and are an internationally proven concept.
Examples already developed by KLSC include:
Life Sciences Academy – a knowledge transfer platform
Innomedics – a medical devices commercialization platform
Newbridges – a pharmaceutical commercialization platform
KLSC invest in companies with products or services which solve existing customer problems with ground-breaking technologies and have the potential for above average, substantial growth.Through many years of experience in direct venture capital investments and investing in world class venture capital funds, KLSC has developed a systematic process based on proprietary thought selection, comprehensive due diligence, and an active investment management.
The focus is pre-commercialization stage companies that are viable and financially attractive with clear exit strategies and a vision to expand into new markets such as Kuwait and the MENA region.
Examples of investments by KLSC include:
Quanta Fluid Solutions – a market leader in (home) hemodialysis solutions
Supersonic Imagine – a market leader in ultrasound imaging
Median Technologies – a market leader in oncology monitoring and imaging
KLSC also invests in more established companies with the purpose of reducing the time gap of certain in-demand technology introduction into the mass markets that follow the existing technology transfer platforms identified by KLSC for the Life Sciences Industry.KLSC invests in the form of private equity in established life science and healthcare companies that have the potential of regional expansion, and a proven concept with sustainable business model.
Examples of investments by KLSC include:
Clinart – a clinical research (contract resource organization) platform
eCore – an industrial (specialty chemicals) platform